Table 1

Baseline characteristics of included patients (n=1620)

Age, years, mean (SD)55 (14.7)
Gender, male, n (%)655 (40.4)
Duration of ETA, n (%)1 year78 (4.8)
2 years106 (6.5)
3 years176 (10.9)
4 years207 (12.8)
5 years205 (12.7)
>5 years848 (52.3)
Comorbidities*, n (%)1 Certain infectious and parasitic diseases42 (2.6)
2 Neoplasms78 (4.8)
3 Diseases of blood and blood forming organs26 (1.6)
4 Endocrine, nutritional, metabolic diseases134 (8.3)
5 Mental and behavioural disorders17 (1.0)
6 Diseases of the nervous system67 (4.1)
7 Diseases of eye and adnexa72 (4.4)
8 Diseases of ear and mastoid35 (2.2)
9 Diseases of circulatory system175 (10.8)
10 Diseases of respiratory system109 (6.7)
11 Diseases of digestive system157 (9.7)
12 Diseases of skin and subcutaneous system143 (8.8)
13 Diseases of musculoskeletal system and connective tissue1598 (98.6)
14 Diseases of genitourinary system113 (7.0)
15 Pregnancy, childbirth and puerperium15 (0.9)
16 Conditions in perinatal period
17 Congenital malformations, deformations, chromosomal abnormalities16 (1.0)
18 Symptoms, signs and abnormal clinical etc199 (12.3)
19 Injury, poisoning, consequences of external causes185 (11.4)
20 External causes of morbidity and mortality
21 Factors influencing health status and contact with health services863 (53.3)
  • *WHO diagnosis chapters 12–24 months previously.

  • ETA, originator etanercept.